Vyndamax
Vyndamax ingredients
| Active ingredient | Strength |
|---|---|
| Tafamidis | 61 mg/1 |
What Vyndamax is used for
The FDA lists the approved uses on the official label (below). In the EU, tafamidis is approved as Vyndaqel for:
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vyndamax
- Generic name
- Tafamidis
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Capsule, Liquid Filled
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA212161
- On the US market since
- 2019
Official information
- Vyndamax prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tafamidis)
In India
- Tafamidis: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vyndamax?
Vyndamax (Tafamidis) is a specialist medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Vyndamax?
Vyndamax contains Tafamidis (61 mg/1).
Is Vyndamax approved in Europe?
The same active substance is approved in the EU as Vyndaqel.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA